Skip to content

Integrative Proteomic Characterization of PDAC

Integrative Proteomic Characterization of PDAC

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036067
Enrollment
Unknown
Registered
2020-08-21
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreactic Cancer

Interventions

PDAC patients:N/A

Sponsors

Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: (1) The diagnosis of pancreatic cancer was confirmed by histological examination or fine needle aspiration cytology; (2) The tumor was graded according to THE WHO standard, and the tumor stage was graded according to the TNM stage;

Exclusion criteria

Exclusion criteria: (1) There are few tissue specimens, only enough for clinical diagnosis; (2) Patients are unwilling to conduct follow-up study; (3) For new patient, radiotherapy or chemotherapy have been given in the previous three months.

Design outcomes

Primary

MeasureTime frame
proteomics;RNA transcriptome profiling;DNA mutation;

Countries

China

Contacts

Public ContactChen Hao

Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine

haochendr@126.com+86 13003135899

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026